Literature DB >> 26256053

The N-Terminal T-T Motif of a Third-Generation HIV-1 Fusion Inhibitor Is Not Required for Binding Affinity and Antiviral Activity.

Huihui Chong1, Zonglin Qiu1, Yang Su1, Yuxian He1.   

Abstract

The highlighted next-generation HIV-1 fusion inhibitor peptide 1 is capped by two threonines. Here, we generated peptide 2 by deleting the T-T motif and compared their structural and antiviral properties. Significantly, two peptides showed similar helical and oligomeric states in solution, comparable binding affinities to the target, and no significant difference to inhibit HIV-1 fusion and infection. Also, the T-T motif was not associated with peptide 1 resistant mutations and its deletion did not affect peptide 1 against enfuvirtide-resistant HIV-1 mutants. The redundancy of the T-T motif was further verified by the model peptide C34 and short peptide inhibitors that mainly target the gp41 pocket, suggesting that the N-terminal T-T motif of peptide 1 could be removed or modified toward the development of new anti-HIV-1 drugs. Consistently, our data have verified that the M-T hook structure rather than the T-T motif is an efficient strategy for short peptide fusion inhibitors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26256053     DOI: 10.1021/acs.jmedchem.5b00109

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent In Vitro, Ex Vivo, and In Vivo Antiviral Activity.

Authors:  Huihui Chong; Jing Xue; Shengwen Xiong; Zhe Cong; Xiaohui Ding; Yuanmei Zhu; Zixuan Liu; Ting Chen; Yifan Feng; Lei He; Yan Guo; Qiang Wei; Yusen Zhou; Chuan Qin; Yuxian He
Journal:  J Virol       Date:  2017-05-12       Impact factor: 5.103

2.  Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity.

Authors:  Yuanmei Zhu; Huihui Chong; Danwei Yu; Yan Guo; Yusen Zhou; Yuxian He
Journal:  J Virol       Date:  2019-05-15       Impact factor: 5.103

3.  Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.

Authors:  Huihui Chong; Yuanmei Zhu; Danwei Yu; Yuxian He
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

4.  Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket.

Authors:  Xiujuan Zhang; Yuanmei Zhu; Hao Hu; Senyan Zhang; Pengfei Wang; Huihui Chong; Jinsheng He; Xinquan Wang; Yuxian He
Journal:  Front Cell Infect Microbiol       Date:  2018-02-26       Impact factor: 5.293

5.  Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.

Authors:  Xiuzhu Geng; Zixuan Liu; Danwei Yu; Bo Qin; Yuanmei Zhu; Sheng Cui; Huihui Chong; Yuxian He
Journal:  Viruses       Date:  2019-07-03       Impact factor: 5.048

Review 6.  Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.

Authors:  Antoinette G Nelson; Xiaoping Zhang; Usha Ganapathi; Zoltan Szekely; Charles W Flexner; Andrew Owen; Patrick J Sinko
Journal:  J Control Release       Date:  2015-08-24       Impact factor: 9.776

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.